Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.
The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.
The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.
In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.
It added the combination therapy was well-tolerated, with no increased side effect burden.
Corcept said it plans to submit a new drug application for the therapy in Q3.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。